An immune drug developer raises $50M to finance its eczema drug testing [Yahoo! Finance]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Yahoo! Finance
TRexBio, a life sciences startup developing treatments for immune conditions, announced Tuesday it raised $50 million in an extension of its Series B round to bankroll testing of its atopic dermatitis drug, among others. Its experimental treatment TRB-061 is in Phase 1 testing , with results expected as soon as 2027. TRex's technology is based on the activation of regulatory T cells, also known as Tregs, which control inflammation and tissue healing. Several biotechs are studying how drugs can train Treg cells to find and suppress antigens that cause overactive immune responses. TRex is looking to activate specific types of Tregs with its drugs. TRB-061, for instance, goes after a protein involved in inflammation called tumor necrosis factor receptor 2. TRex theorizes that by pursuing TNFR2, which is present but under-expressed in atopic dermatitis, it can control the disease without broadly suppressing the immune system like existing eczema drugs. The company is also planning
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics (NKTR): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $118.00 price target on the stock.MarketBeat
- Nektar Therapeutics (NASDAQ:NKTR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
NKTR
Earnings
- 11/6/25 - Beat
NKTR
Sec Filings
- 1/30/26 - Form SCHEDULE
- 1/27/26 - Form 8-K
- 1/22/26 - Form 4
- NKTR's page on the SEC website